Recovery from foetal hypothyroidism: evidence for the safety of breast-feeding while taking propylthiouracil.
We assessed the post-natal thyroid function in eight infants of mothers with Graves' disease whose thyroid function at birth was suppressed by maternal ingestion of propylthiouracil during pregnancy. These mothers continued taking propylthiouracil after delivery and breast-fed exclusively (two mothers supplemented their breast milk with a small amount of baby food). The cord free T4 level was slightly but uniformly below the normal range in all eight infants, and the cord TSH level was above the normal in seven infants. The dose of propylthiouracil after delivery ranged from 50 to 300 mg daily, which was equal to, or higher than, that before delivery. All these abnormal values normalized in the infant after birth. Serum samples, from seven of the eight mothers, taken at delivery were examined for TSH receptor antibodies; all were positive. The antibody titre, however, was too low, and/or free T4 and TSH levels were examined too long after delivery, for the antibodies to be the cause of the restoration of the infants' thyroid function. These results assure the safety of breast-feeding for the infants of mothers with Graves' disease taking propylthiouracil.
Momotani
N
N
Ito Hospital, Tokyo, Japan.
Yamashita
R
R
Yoshimoto
M
M
Noh
J
J
Ishikawa
N
N
Ito
K
K
D000328:Adult; D001942:Breast Feeding; D005260:Female; D005315:Fetal Diseases / Q000139:chemically induced*; D006111:Graves Disease / Q000188:drug therapy; D006801:Humans; D007037:Hypothyroidism / Q000139:chemically induced*; D007231:Infant, Newborn; D008431:Maternal-Fetal Exchange; D011247:Pregnancy; D011441:Propylthiouracil / Q000494:pharmacology*; D013961:Thyroid Gland / Q000187:drug effects; D013972:Thyrotropin / Q000097:blood; D013974:Thyroxine / Q000097:blood
D011441:Propylthiouracil; D013972:Thyrotropin; D013974:Thyroxine